fda - Search News

News

FDA Appoints Biotech Exec

Biotech exec George Tidmarsh picked as FDA's chief drug regulator

The U.S. Food and Drug Administration named ex-biotech exec George Tidmarsh as its chief drug regulator. FDA Commissioner Marty Makary called Tidmarsh an "accomplished physician-scientist and leader."

Associated Press News on MSN · 4h

FDA names former pharmaceutical company executive to oversee US drug program

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

USA TODAY · 3h

FDA appoints biotech veteran George Tidmarsh to lead drug evaluation division

Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing seven FDA-approved drugs.

FDA suspends muscular dystrophy drug

Newsweek on MSN · 17h

FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments.

MedPage Today · 3h

Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths

The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying the agency was investigating the three deaths due to acute liver failure following treatment with Sarepta's AAVrh74 gene therapies.

InvestorsHub on MSN · 6h

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD).

FDA recalls over 67,000 cases of Power Stick deodorant

Austin American-Statesman on M… · 8h

FDA recalls over 67,000 cases of Power Stick deodorant due to manufacturing violations

On July 10, Pennsylvania-based health and beauty manufacturer A.P. Deauville announced a recall of 67,214 cases of its Power Stick roll-on deodorant due to violations of Current Good Manufacturing Practice (CGMP) standards, a set of FDA-enforced guidelines designed to ensure product safety and quality.

al.com · 35m

FDA deodorant recall is nationwide: What should you do if you own one of the products?

The Food and Drug Administration has recalled more than 67,000 cases of deodorant sold at major retailers due to manufacturing practices that violate federal regulations.

TODAY on MSN · 1h

The FDA just recalled 67,000 cases of deodorant — here’s what you need to know

But one thing we’re confident about is that nobody wants to use a deodorant that has been recalled, which is why we are sharing this news: The Food and Drug Administration has issued a recall on 67,000 cases of Power Stick antiperspirant deodorant.

5hon MSN

FDA issues highest risk Warning for mushroom recall

Mushrooms sold across two states have been recalled over fears they could be harboring listeria, a bug that "can cause ...

FDA Elevates Dubai Chocolate Spread Recall to Class 1 Over Salmonella Risk

Salmonella can cause serious and potentially fatal infections in young children, the frail or elderly, and others with ...

8hon MSN

FDA Greenlights Game-Changing UV Technology That Could Make Raw Milk Safer to Consume

Tamarack Biotics’ TruActive process targets pathogens with UV light while keeping the milk’s enzymes and proteins intact.

4hon MSN

FDA Issues Bread Recall Update After Glass Discovered in Crusts

For consumers, the FDA and Upper Crust Bakery LP advised that bread with affected lot numbers should not be consumed but instead discarded or returned to the point of purchase for a refund. Health ...

Las Vegas Sun1d

Juul’s FDA approval doesn’t clear fog of e-cigarette risks, especially for teens

The Food and Drug Administration has granted permission for Juul to continue selling its e-cigarettes, offering some reprieve ...

Targeted Oncology9h

FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

FDA Appoints Biotech Exec

FDA suspends muscular dystrophy drug

FDA recalls over 67,000 cases of Power Stick deodorant

Related topics